{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "17436554",
  "DateCompleted": {
    "Year": "2007",
    "Month": "05",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2007",
    "Month": "04",
    "Day": "17"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1367-6733",
      "JournalIssue": {
        "Volume": "10",
        "Issue": "2",
        "PubDate": {
          "Year": "2007",
          "Month": "Mar"
        }
      },
      "Title": "Current opinion in drug discovery & development",
      "ISOAbbreviation": "Curr Opin Drug Discov Devel"
    },
    "ArticleTitle": "Discovery and development of therapeutic cancer vaccines.",
    "Pagination": {
      "StartPage": "185",
      "EndPage": "192",
      "MedlinePgn": "185-92"
    },
    "Abstract": {
      "AbstractText": [
        "Over the past century, various efforts have been made to induce the rejection of cancerous tissues by the stimulation of an immune reaction, using both non-specific and antigen-specific strategies. Non-specific approaches attempt to augment an immune response in and around the tumor by injecting immune stimulating substances, for example, bacterial extracts, cytokines or gene therapy agents. Antigen-specific approaches use either the tumor cells themselves as a source of antigens or incorporate identified tumor-associated antigens into vaccines. This review describes antigen-specific therapeutic cancer vaccines that are currently in development."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Transgene SA, Department of Medical Affairs, 11 rue de Molsheim, 67082 Strasbourg, France. acres@transgene.fr"
          }
        ],
        "LastName": "Acres",
        "ForeName": "Bruce",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Limacher",
        "ForeName": "Jean-Marc",
        "Initials": "JM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bonnefoy",
        "ForeName": "Jeanoy",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Curr Opin Drug Discov Devel",
    "NlmUniqueID": "100887519",
    "ISSNLinking": "1367-6733"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cancer Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Cancer Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [
        "immunology",
        "prevention & control",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    }
  ],
  "NumberOfReferences": "68"
}